Premenstrual syndrome

The Lancet

Volumn 371, Issue 9619, 2008, Pages 1200-1210

  Yonkers, Kimberly Ann ^a   O'Brien, PM Shaughn ^b   Eriksson, Elias ^c  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b KEELE UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; BENZODIAZEPINE; BUSPIRONE; CITALOPRAM; CLOMIPRAMINE; DANAZOL; DROSPIRENONE; ESCITALOPRAM; ESTRADIOL; ESTROGEN; ETHINYLESTRADIOL; FLUOXETINE; GESTAGEN; GONADORELIN AGONIST; GONADORELIN DERIVATIVE; LEVONORGESTREL; LITHIUM; ORAL CONTRACEPTIVE AGENT; PAROXETINE; PROGESTERONE; PSYCHOTROPIC AGENT; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SEX HORMONE; SPIRONOLACTONE; TIBOLONE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VENLAFAXINE;

BEHAVIOR DISORDER; BLOATING; BRAIN; BREAST TENDERNESS; CLINICAL FEATURE; DAILY LIFE ACTIVITY; DEPRESSION; DIAGNOSTIC TEST; DISEASE SEVERITY; DRUG DEPENDENCE; DYSPHORIA; ENDOMETRIUM HYPERPLASIA; HORMONE BLOOD LEVEL; HUMAN; HYPOTHALAMUS HYPOPHYSIS SYSTEM; IRRITABILITY; LACRIMATION DISORDER; LIBIDO; LUTEAL PHASE; MASTALGIA; MENSTRUAL CYCLE; MOOD CHANGE; MOOD DISORDER; NAUSEA; NERVOUSNESS; NEUROTRANSMISSION; NONHUMAN; OVARY; OVARY CYCLE; PATHOPHYSIOLOGY; PREMENSTRUAL DYSPHORIC DISORDER; PREMENSTRUAL SYNDROME; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SEDATION; SEROTONINERGIC SYSTEM; SEXUAL DYSFUNCTION; SIDE EFFECT; SKIN IRRITATION; TENSION; XEROSTOMIA;

EID: 41449084089     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(08)60527-9     Document Type: Review

References (180)

1. Frank R. The hormonal causes of premenstrual tension. Arch Neurol Psychiatry 26 (1931) 1053-1057
2. Greene R., and Dalton K. The premenstrual syndrome. BMJ 1 (1953) 1007-1014
3. American Psychiatric Association. Diagnostic and statistical manual of mental disorders-DSM-III. 3rd edn (1980), American Psychiatric Association, Washington DC
4. American Psychiatric Association. Diagnostic and statistical manual of mental disorders-DSM-IV. 4th edn (1994), American Psychiatric Association, Washington DC
5. ACOG. ACOG practice bulletin: premenstrual syndrome. Int J Gynecol Obstet 73 (2001) 183-191
6. Johnson S., McChesney C., and Bean J. Epidemiology of premenstrual symptoms in a nonclinical sample-I: Prevalence, natural history and help-seeking behavior. J Repro Med 33 (1988) 340-346
7. Deuster P., Adera T., and South-Paul J. Biological, social, and behavioral factors associated with premenstrual syndrome. Arch Fam Med 8 (1999) 122-128
8. Ramacharan S., Love E., Fick G., and Goldfien A. The epidemiology of premenstrual symptoms in a population based sample of 2650 urban women. J Clin Epidemiol 45 (1992) 377-381
9. Woods N., Most A., and Dery G. Prevalence of perimenstrual symptoms. Am J Public Health 72 (1982) 1257-1264
10. Andersch B., Wendestam C., Hahn L., and Ohman R. Premenstrual complaints. Prevalence of premenstrual symptoms in a Swedish urban population. J Psychosom Obstet Gynaecol 5 (1986) 39-49
11. Angst J., Sellaro R., Merikangas K., and Endicott J. The epidemiology of perimenstrual psychological symptoms. Acta Psychiatr Scand 104 (2001) 110-116
12. Wittchen H., Becker E., Lieb R., and Krause P. Prevalence, incidence and stability of premenstrual dysphoric disorder in the community. Psychol Med 32 (2002) 119-132
13. Rivera-Tovar A., and Frank E. Late luteal phase dysphoric disorder in young women. Am J Psychiatry 147 (1990) 1634-1636
14. Soares C., Cohen L., Otto M., and Harlow B. Characteristics of women with premenstrual dysphoric disorder (PMDD) who did or did not report history of depression: a preliminary report from the Harvard study of moods and cycles. J Women's Health Gend Based Med 10 (2001) 873-878
15. Borenstein J., Dean B., Endicott J., et al. Heath and economic impact of the premenstrual syndrome. J Reprod Med 48 (2003) 515-524
16. Pearlstein T., Yonkers K., Fayyad R., and Gillespie J. Pretreatment pattern of symptom expression in premenstrual dsyphoric disorder. J Affect Disord 85 (2005) 275-282
17. Meaden P., Hartlage S., and Cook-Kerr J. Timing and severity of symptoms associated with the menstrual cycle in a community-based sample in the Midwestern United States. Psychiatr Res 134 (2005) 27-36
18. Sternfeld B., Swindle R., Chawla A., Long S., and Kennedy S. Severity of premenstrual symptoms in a health maintenance organization population. Obstet Gynecol 99 (2002) 1014-1024
19. Bloch M., Schmidt P., and Rubinow D. Premenstrual syndrome: Evidence for symptom stability across cycles. Am J Psychiatry 154 (1997) 1741-1746
20. Steiner M., and Born L. Diagnosis and treatment of premenstrual dysphoric disorder: an update. Int Clin Psychopharmacol 15 suppl 3 (2000) S5-S17
21. Pearlstein T., Frank E., Rivera-Tovar A., Thoft J., Jacobs E., and Mieczkowski T. Prevalence of axis I and axis II disorders in women with late luteal phase dysphoric disorder. J Affect Disord 20 (1990) 129-134
22. Halbreich U., and Endicott J. Relationship of dysphoric premenstrual changes to depressive disorder. Acta Psychiatrica Scandinavica 71 (1985) 331-338
23. Mackenzie T., Wilcox K., and Baron H. Lifetime prevalence of psychiatric disorders in women with perimenstrual difficulties. J Affect Disord 10 (1986) 15-19
24. Richards M., Rubinow D., Daly R., and Schmidt P. Premenstrual symptoms and perimenopausal depression. Am J Psychiatry 163 (2006) 133-137
25. Studd J., and Smith R. Estrogens and depression in women. Menopause: J North Am Menopause Soc 1 (1994) 33-37
26. Bloch M., Schmidt P., Danaceau M., Murphy J., Nieman L., and Rubinow D. Effects of gonadal steroids in women with a history of postpartum depression. Am J Psychiatry 157 (2000) 924-930
27. Landen M., and Eriksson E. How does premenstrual dysphoric disorder relate to depression and anxiety disorders?. Depress Anxiety 17 (2003) 122-129
28. Yonkers K. Anxiety symptoms and anxiety disorders: How are they related to premenstrual disorders. J Clin Psychiatry 58 (1997) 62-67
29. Rosseinsky D., and Debonnel P. An evolutionary theory of premenstrual tension. Lancet 2 (1974) 1024
30. Rapkin A., Pollack D., Raleigh M., Stone B., and McGuire M. Menstrual cycle and social behavior in vervet monkeys. Psychoneuroendocrinology 20 (1995) 289-297
31. Ho H.-P., Olsson M., Westberg L., Melke J., and Eriksson E. The serotonin reuptake inhibitor fluoxetine reduces sex steroid-related aggression in female rats: an animal model of premenstrual irritability?. Neuropsychopharmacology 24 (2001) 502-510
32. Hyde J., and Sawyer T. Estrous cycle fluctuations in aggressiveness of house mice. Horm Behav 9 (1977) 290-295
33. MacDonald P., Dombroski R., and Casey M. Recurrent secretion of progesterone in large amounts: An endocrine/metabolic disorder unique to young women?. Endocrine Rev 12 (1991) 372-401
34. Hammarback S., Ekholm U.-B., and Backstrom T. Spontaneous anovulation causing disappearance of cyclical symptoms in women with the premenstrual syndrome. Acta Endocrinologica 125 (1991) 132-137
35. Casper R., and Hearn M. The effect of hysterectomy and bilateral oophorectomy in women with severe premenstrual syndrome. Am J Obstet Gynecol 162 (1990) 105-109
36. Casson P., Hahn P., Van Vugt D., and Reid R. Lasting response to ovariectomy in severe intractable premenstrual syndrome. Am J Obstet Gynecol 162 (1990) 99-105
37. Cronje W., Vashisht A., and Studd J. Hysterectomy and bilateral oophorectomy for severe premenstrual syndrome. Hum Reprod 19 (2004) 2152-2155
38. Muse K., Cetel N., Futterman L., and Yen S. The premenstrual syndrome: Effects of "medical ovariectomy". N Engl J Med 311 (1984) 1345-1349
39. Bancroft J., Boyle H., Warner P., and Fraser H. The use of an LHRH agonist, buserelin, in the long-term management of premenstrual syndromes. Clin Endocrinol 27 (1987) 171-182
40. Hammarback S., and Backstrom T. Induced anovulation as treatment of premenstrual tension syndrome: a double-blind cross-over study with GnRH-agonist versus placebo. Acta Obstet Gynecol Scand 67 (1988) 159-166
41. Wyatt K., Dimmock P., Ismail K., Jones P., and O'Brien P. The effectiveness of GnRHa with and without 'add-back' therapy in treating premenstrual syndrome: a meta analysis. BJOG: Int J Obstet Gynaecol 111 (2004) 585-593
42. Magos A., Brewster E., Singh R., O'Dowd T., Brincat M., and Studd J. The effects of norethisterone in postmenopausal women on oestrogen replacement therapy: a model for the premenstrual syndrom. BJOG 93 (1986) 1290-1296
43. Henshaw C., Foreman D., Belcher J., Cox J., and O'Brien S. Can one induce premenstrual symptomatology in women with prior hysterectomy and bilateral oophorectomy?. J Psychosom Obstet Gynecol 17 (1996) 21-28
44. Leather A., Studd J., Watson N., and Holland E. The treatment of severe premenstrual syndrome with goserelin with and without "add-back" estrogen therapy: a placebo-controlled study. Gynecol Endocrinol 13 (1999) 48-55
45. Schmidt P., Nieman L., Danaceau M., Adams L., and Rubinow D. Differential behavioral effects of gonadal steriods in women with and in those without premenstrual syndrome. N Engl J Med 338 (1998) 209-216
46. Smith S., Ruderman Y., Frye C., Homanics G., and Yuan M. Steroid withdrawal in the mouse results in anxiogenic effects of 3alpha, 5beta-THP: a possible model of premenstrual dysphoric disorder. Psychopharmacology 29 (2005) 1-11
47. Poromaa I.S., Smith S., and Gulinello M. GABA receptors, progesterone and premenstrual dysphoric disorder. Arch Women Ment Health 6 (2003) 23-41
48. Wyatt K., Dimmock P., Jones P., Obhrai M., and O'Brien S. Efficacy of progesterone and progestogens in management of premenstrual syndrome: systematic review. BMJ 323 (2001) 776-781
49. Schmidt P., Nieman L., Grover G., Muller K., Merriam G., and Rubinow D. Lack of effect of induced menses on symptoms in women with premenstrual syndrome. N Engl J Med 324 (1991) 1174-1179
50. Hammarback S., Backstrom T., Holst J., von Schoultz B., and Lyrenas S. Cyclical mood changes as in the premesntrual tension syndrome during sequential estrogen-progestagen posmenopausal replacement therapy. Acta Obstet Gynecol Scand 64 (1985) 393-397
51. Schmidt P. Depression, the perimenopause, and estrogen therapy. Ann NY Acad Sci 1052 (2005) 27-40
52. Bjorn I., Sundstrom-Poromaa I., Bixo M., Nyberg S., Backstrom G., and Backstrom T. Increase of estrogen dose deteriorates mood during progestin phase in sequential hormonal therapy. J Clin Endocrinol Metab 88 (2003) 2026-2030
53. Dhar V., and Murphy B. Double-blind randomized crossover trial of luteal phase estrogens (Premarin) in the premenstrual syndrome (PMS). Psychoneuroendocrinology 15 (1991) 489-493
54. Oksa S., Luukkaala T., and Maenpaa J. Toremifene for premenstrual mastalgia: a randomised, placebo-controlled crossover study. BJOG 113 (2006) 713-718
55. Rubinow D., and Schmidt P. The neuroendocrinology of menstrual cycle mood disorders. Ann N Y Acad Sci 771 (1995) 648-659
56. Condon J. The premenstrual syndrome: A twin study. Br J Psychiatry 162 (1993) 481-486
57. Kendler K., Karkowski L., Corey L., and Neale M. Longitudinal population-based twin study of retrospectively reported premenstrual symptoms and lifetime major depression. Am J Psychiatry 155 (1998) 1234-1240
58. Treloar S., Heath A., and Martin N. Genetic and environmental influences on premenstrual symptoms in an Australian twin sample. Psychol Med 32 (2002) 25-38
59. Masho S., Adera T., and South-Paul J. Obesity as a risk factor for premenstrual syndrome. J Psychosom Obstet Gynaecol 26 (2005) 33-39
60. Perkonigg A., Yonkers K., Pfister H., Lieb R., and Wittchen H. Risk factors for premenstrual dysphoric disorder in a community sample of young women: The role of traumatic events and posttraumatic stress disorder. J Clin Psychiatry 65 (2004) 1314-1322
61. Girdler S., Pedersen C., and Light K. Thyroid axis function during the menstrual cycle in women with premenstrual syndrome. Psychoneuroendocrinol 20 (1995) 395-403
62. Schmidt P., Grover G., Roy-Byrne P., et al. Thyroid function in women with premenstrual syndrome. J Clin Endocrinol Metab 76 (1993) 671-674
63. Parry B., and Newton R. Chronobiological basis of female-specific mood disorders. Neuropsychopharmacology 25 suppl 5 (2001) S102-S108
64. Hariri A., Mattay V., Tessitore A., et al. Serotonin transporter genetic variation and the response of the human amygdala. Science 297 (2002) 400-403
65. Caspi A., Sugden K., Moffitt T., et al. Influence of life stress on depression: Moderation by a polymorphism in the 5-HTT gene. Science 301 (2003) 386-389
66. Parsey R., Hastings R., Oquendo M., et al. Lower serotonin transporter binding potential in the human brain during major depressive episodes. Am J Psychiatry 163 (2006) 52-58
67. Eriksson E., Andersch B., Ho H., Landen M., and Sundblad C. Diagnosis and treatment of premenstrual dysphoria. J Clin Psychiatry 63 suppl 7 (2002) 16-23
68. Gregorian R., Golden K., Bahce A., Goodman C., Kwong W., and Khan Z. Antidepressant-induced sexual dysfunction. Ann Pharmacother 36 (2002) 1577-1589
69. Sundblad C., Wikander I., Andersch B., and Eriksson E. A naturalistic study of paroxetine in premenstrual syndrome: efficacy and side effects during ten cycles of treatment. Eur Neuropsychopharmacology 7 (1997) 201-206
70. Carlsson M., and Carlsson A. A regional study of sex differences in rat brain serotonin. Prog Neuro-Psychopharmacol Biol Psychiatry 12 (1988) 53-61
71. Hiroi R., McDevitt R., and Neumaier J. Estrogen selectively increases tryptophan hydroxylase-2 mRNA expression in distinct subregions of rat midbrain raphe nucleus: association between gene expression and anxiety behavior in the open field. Biol Psychiatry 60 (2006) 288-295
72. Rubinow D., Schmidt P., and Roca C. Estrogen-serotonin interactions: implications for affective regulation. Biol Psychiatry 44 (1998) 839-850
73. Bethea C., Lu N., Gundlah C., and Streicher J. Diverse actions of ovarian steroids in the serotonin neural system. Front Neuroendocrinol 23 (2002) 41-100
74. Brzezinski A., Wurtman J., Wurtman R., Gleason R., Greenfield J., and Nader T. d-fenfluramine suppresses the increased calorie and carbohydrate intakes and improves the mood of women with premenstrual depression. J Am Coll Obstet Gynecol 76 (1990) 296-300
75. Su T.-P., Schmidt P., Danaceau M., Murphy D., and Rubinow D. Effect of menstrual cycle phase on neuroendocrine and behavioral responses to the serotonin agonist m-chlorophenylpiperazine in women with premenstrual syndrome and controls. J Clin Endocrinol Metab 82 (1997) 1220-1228
76. Steinberg S., Annable L., Young S., and Liyanage N. A placebo-controlled clinical trial of L-tryptophan in premenstrual dysphoria. Biol Psychiatry 45 (1999) 313-320
77. Landen M., Eriksson O., Sundblad C., Andersch B., Naessen T., and Eriksson E. Compounds with affinity for serotonergic receptors in the treatment of premenstrual dysphoria: a comparison of buspirone, nefazodone and placebo. Psychopharmacology 155 (2001) 292-298
78. Menkes D., Coates D., and Fawcett J. Acute tryptophan depletion aggravates premenstrual syndrome. J Affect Disord 32 (1994) 37-44
79. Roca C., Schmidt P., Smith M., Danaceau M., Murphy D., and Rubinow D. Effects of metergoline on symptoms in women with premenstrual dysphoric disorder. Am J Psychiatry 159 (2002) 1876-1881
80. Bancroft J., Cook A., Davidson D., Bennie J., and Goodwin G. Blunting of neuroendocrine responses to infusion of L-tryptophan in women with perimenstrual mood change. Psychol Med 21 (1991) 305-312
81. Eriksson O., Wall A., Marteinsdottir I., et al. Mood changes correlate to changes in brain serotonin precursor trapping in women with premenstrual dysphoria. Psychiatry Res 146 (2006) 107-116
82. Fitzgerald M., Malone K., Li S., et al. Blunted serotonergic response to fenfluramine challenge in premenstrual dysphoric disorder. Am J Psychiatry 154 (1997) 556-558
83. Halbreich U., and Tworek H. Altered serotonergic activity in women with dysphoric premenstrual syndromes. Int J Psychiatry Med 23 (1993) 1-27
84. Rojansky N., Halbreich U., Zander K., Barkai A., and Goldstein S. Imipramine receptor binding and serotonin uptake in platelets of women with premenstrual changes. Gynecol Obstet Investig 31 (1991) 146-152
85. Steege J., Stout A., Knight B., and Nemeroff C. Reduced platelet tritium-labeled imipramine binding sites in women with premenstrual syndrome. Am J Obstet Gynecol 167 (1992) 168-172
86. Rasgon N., McGuire M., Tanavoli S., Fairbanks L., and Rapkin A. Neuroendocrine response to an intravenous L-tryptophan challenge in women with premenstrual syndrome. Fertil Steril 73 (2000) 144-149
87. Steiner M., LN Y., Coote M., Wilkins A., and Lepage P. Serotonergic dysfunction in women with pure premenstrual dysphoric disorder: is the fenfluramine challenge test still relevant. Psychiatry Res 87 (1999) 107-115
88. Yatham L., Barry S., and Dinan T. Serotonin receptors, buspirone, and premenstrual syndrome. Lancet 1 (1989) 1447-1448
89. Melke J., Westberg L., Landen M., et al. Serotonin transporter gene polymorphisms and platelet [3H] paroxetine binding in premenstrual dysphoria. Psychoneuroendocrinology 28 (2003) 446-458
90. Epperson C., Haga K., Mason G., et al. Cortical gamma-aminobutyric acid levels across the menstrual cycle in healthy women and those with premenstrual dysphoric disorder: A proton magnetic resonance spectroscopy study. Arch Gen Psychiatry 59 (2002) 851-858
91. Sundstrom I., Ashbrook D., and Backstrom T. Reduced benzodiazepine sensitivity in patients with premenstrual syndrome: a pilot study. Psychoneuroendocrinol 22 (1997) 25-38
92. Schmidt P., Purdy R., Moore P., Paul S., and Rubinow D. Circulating levels of anxiolytic steroids in the luteal phase in women with premenstrual syndrome and in control subjects. J Clin Endocrinol Metab 79 (1994) 1256-1260
93. Rapkin A., Morgan M., Goldman L., Brann D., Simone D., and Mahesh V. Progesterone metabolite allopregnanolone in women with premenstrual syndrome. Obstet Gynecol 90 (1997) 709-714
94. Girdler S., Straneva P., Light K., Pederson C., and Morrow A. Allopregnanolone levels and reactivity to mental stress in premenstrual dysphoric disorder. Biol Psychiatry 49 (2001) 788-797
95. Schmidt P., Grover G., and Rubinow D. Alprazolam in the treatment of premenstrual syndrome: a double-blind, placebo-controlled trial. Arch Gen Psychiatry 50 (1993) 467-473
96. Bhagwagar Z., Wylezinska M., Taylor M., Jezzard P., Matthews P., and Cowen P. Increased brain GABA concentrations following acute administration of a selective serotonin reuptake inhibitor. Am J Psychiatry 161 (2004) 368-370
97. Sundstrom I., and Backstrom T. Citalopram increases pregnanolone sensitivity in patients with premenstrual syndrome: an open trial. Psychoneuroendocrinology 23 (1998) 73-88
98. Pinna G., Costa E., and Guidotti A. Fluoxetine and norfluoxetine stereospecifically and selectively increase brain neurosteroid content at doses that are inactive on 5-HT reuptake. Psychopharmacology (Berl) 186 (2006) 362-372
99. Griffin L., and Mellon S. Selective serotonin reuptake inhibitors directly alter activity of neurosteroidogenic enzymes. Proc Natl Acad Sci USA 96 (1999) 13512-135xs17
100. Faratian B., Gaspar A., O'Brien P., Johnson I., Filshie G., and Prescott P. Premenstrual syndrome: weight, abdominal swelling, and perceived body image. Am J Obstet Gynecol 150 (1984) 200-204
101. Andersch B., Hahn L., Andersson M., and Isaksson B. Body water and weight in patients with premenstrual tension. BJOG 85 (1978) 546-550
102. Andersch B. Bromocriptine and premenstrual symptoms: a survey of double blind trials. Obstet Gynecol Surv 38 (1983) 643-646
103. Ylostalo P., Kauppila A., Puolakka J., Ronnberg L., and Janne O. Bromocriptine and norethisterone in the treatment of premenstrual syndrome. J Am Coll Obstet Gynecol 58 (1981) 292-298
104. Wuttke W., Jarry H., Christoffel V., Spengler B., and Seidlova-Wuttke D. Chaste tree (Vitex agnus-castus)-pharmacology and clinical indications. Phytomedicine 10 (2003) 348-357
105. O'Brien P., and Abukhalil I. Randomized controlled trial of the management of premenstrual syndrome and premenstrual mastalgia using luteal phase-only danazol. Am J Obstet Gynecol 180 (1999) 18-23
106. O'Brien P., Craven D., Selby C., and Symonds E. Treatment of premenstrual syndrome by spironolactone. BJOG 86 (1979) 142-147
107. Bancroft J., and Rennie D. Perimenstrual depression: its relationship to pain, bleeding, and previous history of depression. Psychosom Med 57 (1995) 445-452
108. Endicott J., Nee J., and Harrison W. Daily record of severity of problems (DRSP): reliability and validity. Arch Womens Ment Health 9 (2006) 41-49
109. Wyatt K., Dimmock P., and O'Brien P. Selective serotonin reuptake inhibitors for premenstrual syndrome. Cochrane Database of Syst Rev 3 (2003) CD001396.
110. Yonkers K., Clark R., and Trivedi M. The psychopharmacological treatment of nonmajor mood disorders. In: Rush A. (Ed). Mood disorders: systematic medication management-modern problems of pharmacopsychiatry, II series ed (1997), Karger, Basel 146-166
111. Sundblad C., Modigh K., Andersch B., and Eriksson E. Clomipraine effectively reduces premenstrual irritability and dysphoria: a placebo-controlled trial. Acta Psychiatr Scand 85 (1992) 39-47
112. Sundblad C., Hedberg M., and Eriksson E. Clomipramine administered during the luteal phase reduces the symptoms of premenstrual syndrome: a placebo-controlled trial. Neuropsychopharmacology 9 (1993) 133-145
113. Wikander I., Sundblad C., Andersch B., et al. Citalopram in premenstrual dysphoria: is intermittent treatment during luteal phases more effective than continuous medication throughout the menstrual cycle?. J Clin Psychopharmaocol 18 (1998) 390-398
114. Eriksson E., Nissbrandt H., Sörvik K., et al. Esictalopram in the trestment of premenstrual dysphoric disorder. Eur Neuropsychopharmacol 15 suppl 3 (2005) S636
115. Pearlstein T., Stone A., Lund S., Scheft H., Zlotnick C., and Brown W. Comparison of fluoxetine, buproprion, and placebo in the treatment of premenstrual dysphoric disorder. J Clin Psychopharmacol 17 (1997) 261-265
116. Steiner M., Steinberg S., Stewart D., et al. Fluoxetine in the treatment of premenstrual dysphoria. N Engl J Med 332 (1995) 1529-1534
117. Stone A., Pearlstein T., and Brown W. Fluoxetine in the treatment of late luteal phase dysphoric disorder. J Clin Psychiatry 52 (1991) 290-293
118. Wood S., Mortola J., Chan Y.-F., Moossazadeh F., and Yen S. Treatment of premenstrual syndrome with fluoxetine: a double-blind, placebo-controlled, crossover study. Obstet Gynecol 80 (1992) 339-344
119. Cohen L., Miner C., Brown E., et al. Premenstrual daily fluoxetine for premenstrual dysphoric disorder: a placebo-controlled, clinical trial using computerized diaries. Obstet Gynecol 100 (2002) 435-444
120. Miner C., Brown E., McCray S., Gonzales J., and Wohlreich M. Weekly luteal phase dosing with enteric-coated fluoxetine 90 mg in premenstrual dysphoric disorder: a randomized, double-blind, placebo-controlled clinical trial. Clin Ther 24 (2002) 417-433
121. Eriksson E., Hedberg M., Andersch B., and Sundblad C. The serotonin reuptake inhibitor paroxetine is superior to the noradrenaline reuptake inhibitor maprotiline in the treatment of premenstrual syndrome. Neuropsychopharmacology 12 (1995) 167-176
122. Cohen L., Soares C., Yonkers K., Bellew K., Bridges I., and Steiner M. Paroxetine controlled release for premenstrual dysphoric disorder: a double-blind, placebo-cont rolled trial. Psychosom Med 66 (2004) 707-713
123. Steiner M., Hirschberg A., Bergeron R., Holland F., Gee M., and VanErp E. Luteal phase dosing with paroxetine controlled release (CR) in the treatment of premenstrual dysphoric disorder. Am J Obstet Gynecol 193 (2005) 352-360
124. Yonkers K., Holthausen G., Poschman K., and Howell H. Symptom-onset treatment for women with premenstrual dysphoric disorder. J Clin Psychopharmacol 26 (2006) 198-202
125. Landen M., Nissbrandt H., Allgulander C., Sorvik K., Ysander C., and Eriksson E. Placebo-controlled trial comparing intermittent and continuous paroxetine in premenstrual dysphoric disorder. Neuropsychopharmacology 32 (2007) 153-161
126. Freeman E., Rickels K., Sondheimer S., and Polansky M. Differential reponse to antidepressants in women with premenstrual syndrome/premenstrual dysphoric disorder: a randomized controlled trial. Arch Gen Psychiatry 56 (1999) 932-939
127. Halbreich U., and Smoller J. Intermittent luteal phase sertraline treatment of dysphoric premenstrual syndrome. J Clin Psychiatry 58 (1997) 399-402
128. Jermain D., Preece C., Sykes R., Kuehl T., and Sulak P. Luteal phase sertraline treatment for premenstrual dysphoric disorder: results of a double-blind, placebo-controlled, crossover study. Arch Fam Med 8 (1999) 328-332
129. Young S., Hurt P., Benedek D., and Howard R. treatment of premenstrual dysphoric disorder with sertraline during the luteal phase: a randomized, double-blind, placebo-controlled crossover trial. J Clin Psychiatry 59 (1998) 76-80
130. Freeman E., Rickels K., Sondheimer S., Polansky M., and Xiao S. Continuous or intermittent dosing with sertraline for patients with severe premenstrual syndrome or premenstrual dysphoric disorder. Am J Psychiatry 161 (2004) 343-351
131. Freeman E., Rickels K., Yonkers K., et al. Venlafaxine in the treatment of premenstrual dysphoric disorder. Obstet Gynecol 98 (2001) 737-744
132. Cohen L., Soares C., Lyster A., Cassano P., Brandes M., and Leblanc G. Efficacy and tolerability of premenstrual use of venlafaxine (flexible dose) in the treatment of premenstrual dysphoric disorder. J Clin Psychopharmacol 24 (2004) 540-543
133. Freeman E., Rickels K., Sondheimer S., and Polansky M. Differential response to antidepressants in women with premenstrual syndrome/premenstrual dysphonic disorder: a randomised controlled trial. Arch Gen Psychiatry 56 (1999) 932-939
134. Halbreich U., Bergeron R., Yonkers K., Freeman E., Stout A., and Cohen L. Efficacy of intermittent, luteal phase sertraline treatment of premenstrual dysphoric disorder. Obstet Gynecol 100 (2002) 1219-1229
135. Watson N., Studd J., Savvas M., Garnett T., and Baber R. Treatment of severe premenstrual syndrome with oestradiol patches and cyclical oral norethisterone. Lancet 2 (1989) 730-732
136. Magos A., Brincat M., and Studd J. Treatment of the premenstrual syndrome by subcutaneous estradiol implants and cyclical oral norethisterone: placebo-controlled study. BMJ 292 (1986) 1629-1633
137. Thys-Jacobs S., Starkey P., Bernstein D., and Tian J. Calcium carbonate and the premenstrual syndrome: effects on premenstrual and menstrual symptoms. Premenstrual Syndrome Study Group. Am J Obstet Gynecol 179 (1998) 444-452
138. Yonkers K., Brown C., Pearlstein T., Foegh M., Sampson-Landers C., and Rapkin A. Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstet Gynecol 106 (2005) 492-501
139. Pearlstein T., Bachmann G., Zacur H., and Yonkers K. Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation. Contraception 72 (2005) 414-421
140. Pearlstein T., Halbreich U., Batzar E., et al. Psychosocial functioning in women with premenstrual dysphoric disorder before and after treatment with sertraline or placebo. J Clin Psychiatry 61 (2000) 101-109
141. Steiner M., Brown E., Trzepacz P., et al. Fluoxetine improves functional work capacity in women with premenstrual dysphoric disorder. Arch Women's Ment Health 6 (2003) 71-77
142. Eriksson E., Endicott J., Andersch B., et al. New perspectives on the treatment of premenstrual syndrome and premenstrual dysphoric disorder. Arch Women's Ment Health 4 (2002) 111-119
143. Steiner M., Pearlstein T., Cohen L., et al. Expert guidelines for the treatment of severe PMS, PMDD, and comorbidities: the role of SSRIs. J Women's Health 15 (2006) 57-69
144. Young S., Hurt P., Benedeck D., and Howard R. Treatment of PDD with sertraline during the luteal phase: a randomised, double-blind, placebo controlled crossover trial. J Clin Psychiatry 59 (1998) 76-80
145. Freeman E., Sondheimer S., Sammel M., Ferdousi T., and Lin H. A preliminary study of luteal phase versus symptom-onset dosing with escitalopram for premenstrual dysphoric disorder. J Clin Psychiatry 66 (2005) 769-773
146. Steiner M., Romano S., Babcock S., et al. The efficacy of fluoxetine in improving physical symptoms associated with premenstrual dysphoric disorder. Br J Obstet Gynaecol 108 (2001) 462-468
147. Steiner M., Haskett R., Osmun J., and Carroll B. Treatment of premenstrual tension with lithium carbonate. A pilot study. Acta Psychiatrica Scand 61 (1980) 96-102
148. Pearlstein T., Stone A., Lund S., Scheft H., Zlotnick C., and Brown W. Comparison of fluoxetine, bupropion, and placebo in premenstrual dysphoric disorder. J Clin Psychopharmacol 17 (1997) 261-266
149. Rickels K., Freeman E., and Sondheimer S. Buspirone in treatment of premenstrual syndrome. Lancet 4 (1989) 777
150. Smith S., Rinehart J., Ruddock V., and Schiff I. Treatment of premenstrual syndrome with alprazolam: Results of a double-blind, placebo-controlled, randomized crossover clinical trial. Obstet Gynecol 70 (1987) 37-43
151. Harrison W., Endicott J., and Nee J. Treatment of premenstrual dysphoria with alprazolam. Arch Gen Psychiatry 47 (1990) 270-275
152. Freeman E., Rickels K., Sondheimer S., and Polansky M. A double-blind trail of oral progesterone, alprazolam, and placebo in treatment of severe premenstrual syndrome. JAMA 274 (1995) 51-57
153. Wyatt K., Dimmock P., Frischer M., Jones P., and O'Brien S. Prescribing patterns in premenstrual syndrome. BMC Womens Health 2 (2002) 4
154. Di Carlo C., Palomba S., Tommaselli G., Guida M., Sardo A., and Nappi C. Use of leuprolide acetate plus tibolone in the treatment of severe premenstrual syndrome. Fertil Steril 75 (2001) 380-384
155. Cronje W., and Studd J. Premenstrual syndrome and premenstrual dysphoric disorder. Prim Care 29 (2002) 1-12
156. Watson N., Studd J., Savvas M., and Baber R. The long-term effects of estradiol implant therapy for the treatment of premenstrual syndrome. Gynecol Endocrinol 4 (1990) 99-107
157. O'Brien P., Abukhalil I., and Henshaw C. Premenstrual syndrome. Curr Obstet Gyneacol 5 (1995) 30-35
158. Domoney C., Panay N., Hawkins A., and Studd J. Treatment of premenstrual syndrome with transdermal oestrogen. Int J Gynaecol Obstet 83 suppl 3 (2003) 37
159. Bancroft J., and Rennie D. The impact of oral contraceptives on the experience of perimenstrual mood, clumsiness, food craving and other symptoms. J Psychosom Res 37 (1993) 195-202
160. Graham C., and Sherwin B. A prospective treatment study of premenstrual symptoms using a triphasic oral contraceptive. J Psychosom Res 36 (1992) 257-266
161. Sulak P., Scow R., Preece C., Riggs M., and Kuehl T. Hormone withdrawal symptoms in oral contraceptive users. Obstet Gynecol 95 (2000) 261-266
162. Sulak P., Kuehl T., Ortiz M., and Schull B. Acceptance of altering the standard 21-day/7-day oral contraceptive regimen to delay menses and reduce hormone withdrawal symptoms. Am J Obstet Gynecol 186 (2002) 1142-1149
163. Halbreich U., Rojansky N., and Palter S. Elimination of ovulation and menstrual cyclicity (with danazol) improves dysphoric premenstrual syndromes. Fertil Steril 56 (1991) 1066-1069
164. Watts J., Butt W., and Edwards R. A clinical trial using danazol for the treatment of premenstrual tensiohn. BJOG 94 (1987) 30-34
165. Hahn P., Van Vugt D., and Reid R. A randomized, placebo-controlled, crossover trial of danazol for the treatment of premenstrual syndrome. Psychoneuroendocrinology 20 (1995) 193-199
166. Lam R., Carter D., Misri S., Kuan A., Yatham L., and Zis A. A controlled study of light therapy in women with late luteal phase dysphoric disorder. Psychiatry Res 86 (1999) 185-192
167. Vellacott I., Shroff N., Pearce M., Stratford M., and Akbar F. A double-blind, placebo-controlled evaluation of spironolactone in the premenstrual syndrome. Curr Med Res Opin 10 (1987) 450-456
168. Aslaksen K., and Falk V. Spironolactone in the treatment of premenstrual tension: A double-blind study of spironolactone vs bendroflumethiazide and placebo. Curr Ther Res Clin Exper 49 (1991) 120
169. Wyatt K., Dimmock P., Jones P., and O'Brien P.S. Efficacy of vitamin B-6 in the treatment of premenstrual syndrome: systematic review. BMJ (Clin Res Ed) 318 (1999) 1375-1381
170. Schellenberg R. treatment for the premenstrual syndrome with agnus castus fruit extract: prospective, randomised, placebo controlled study. BMJ 322 (2001) 134-137
171. Budeiri D., Li Wan Po A., and Dornan J. Is evening primrose oil of value in the treatment of premenstrual syndrome?. Control Clin Trials 17 (1996) 60-68
172. Walker A., De Souza M., Marakis G., Robinson P., Morris A., and Bolland K. Unexpected benefit of sorbitol placebo in Mg intervention study of premenstrual symptoms: implications for choice of placebo in RCTs. Med Hypotheses 58 (2002) 213-220
173. Khine K., Rosenstein D., Elin R., Niemela J., Schmidt P., and Rubinow D. Magnesium (mg) retention and mood effects after intravenous mg infusion in premenstrual dysphoric disorder. Biol Psychiatry 59 (2006) 327-333
174. Sayegh R., Schiff I., Wurtman J., Spiers P., McDermott J., and Wurtman R. The effect of a carbohydrate-rich beverage on mood, appetite, and cognitive function in women with premenstrual syndrome. J Am Coll Obstet Gynecol 86 (1995) 520-528
175. Freeman E., Stout A., Endicott J., and Spiers P. treatment of premenstrual syndrome with a carbohydrate-rich beverage. Int J Gynecol Obstet 77 (2002) 253-254
176. Hunter M., Ussher J., Browne S., Cariss M., Jelley R., and Katz M. A randomized comparison of psychological (cognitive behavior therapy), medical (fluoxetine) and combined treatment for women with premenstrual dysphoric disorder. J Psychosom Obstet Gynaecol 23 (2002) 193-199
177. Steege J., and Blumenthal J. The effects of aerobic exercise on premenstrual symptoms in middle-aged women: a preliminary study. J Psychosom Res 37 (1993) 127-133
178. Mira M., McNeil D., Fraser I., Vizzard J., and Abraham S. Mefenamic acid in the treatment of premenstrual syndrome. J Am Coll Obstet Gynecol 68 (1986) 395-398
179. Facchinetti F., Fioroni L., Sances G., Romano G., Nappi G., and Genazzani A. Naproxen sodium in the treatment of premenstrual symptoms: a placebo-controlled study. Gynecol Obstet Investig 28 (1989) 205-208
180. Chuong C., and Hsi B. Effect of naloxone on luteinizing hormone secretion in premenstrual syndrome. Fertil Steril 61 (1994) 1039-1044